Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/155061
Title: Carbene-catalyzed enantioselective annulation of dinucleophilic hydrazones and bromoenals for access to aryl-dihydropyridazinones and related drugs
Authors: Mondal, Bivas
Maiti, Rakesh
Yang, Xing
Xu, Jun
Tian, Weiyi
Yan, Jia-Lei
Li, Xiangyang
Chi, Robin Yonggui
Keywords: Science::Chemistry
Issue Date: 2021
Source: Mondal, B., Maiti, R., Yang, X., Xu, J., Tian, W., Yan, J., Li, X. & Chi, R. Y. (2021). Carbene-catalyzed enantioselective annulation of dinucleophilic hydrazones and bromoenals for access to aryl-dihydropyridazinones and related drugs. Chemical Science, 12(25), 8778-8783. https://dx.doi.org/10.1039/d1sc01891d
Project: NRF-NRFI2016-06
NRF-CRP22-2019-0002
RG108/16
RG5/19
RG1/18
MOE2019-T2-2-117
MOE2018-T3-1-003
A1783c0008
A1783c0010
Journal: Chemical Science
Abstract: 4,5-Dihydropyridazinones bearing an aryl substituent at the C6-position are important motifs in drug molecules. Herein, we developed an efficient protocol to access aryl-dihydropyridazinone molecules via carbene-catalyzed asymmetric annulation between dinucleophilic arylidene hydrazones and bromoenals. Key steps in this reaction include polarity-inversion of aryl aldehyde-derived hydrazones followed by chemo-selective reaction with enal-derived α,β-unsaturated acyl azolium intermediates. The aryl-dihydropyridazinone products accessed by our protocol can be readily transformed into drugs and bioactive molecules.
URI: https://hdl.handle.net/10356/155061
ISSN: 2041-6520
DOI: 10.1039/d1sc01891d
Rights: © 2021 The Author(s). Published by the Royal Society of Chemistry. This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:SPMS Journal Articles

Page view(s)

41
Updated on May 19, 2022

Download(s)

6
Updated on May 19, 2022

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.